TGF-β-miR-34a-CCL22 Signaling-Induced Treg Cell Recruitment Promotes Venous Metastases of HBV-Positive Hepatocellular Carcinoma

Cancer Cell

Volumn 22, Issue 3, 2012, Pages 291-303

  Yang, Pengyuan ^a,c   Li, Qi Jing ^a   Feng, Yuxiong ^b   Zhang, Yun ^a   Markowitz, Geoffrey J ^a   Ning, Shanglei ^a   Deng, Yuezhen ^b   Zhao, Jiangsha ^b   Jiang, Shan ^a   Yuan, Yunfei ^d   Wang, Hong Yang ^c   Cheng, Shu Qun ^c   Xie, Dong ^b   Wang, Xiao Fan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Chinese Academy of Sciences   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; MACROPHAGE DERIVED CHEMOKINE; MICRORNA 34A; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; GENE EXPRESSION; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSURVEILLANCE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PORTAL VEIN TUMOR THROMBUS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

HEPATITIS B VIRUS;

EID: 84866018690     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.07.023     Document Type: Article

References (45)

1. Bao S., Ouyang G., Bai X., Huang Z., Ma C., Liu M., Shao R., Anderson R.M., Rich J.N., Wang X.F. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004, 5:329-339.
2. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
3. Benhenda S., Cougot D., Buendia M.A., Neuveut C. Hepatitis B virus X protein molecular functions and its role in virus life cycle and pathogenesis. Adv. Cancer Res. 2009, 103:75-109.
4. Bierie B., Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006, 6:506-520.
5. Bissell D.M. Chronic liver injury, TGF-beta, and cancer. Exp. Mol. Med. 2001, 33:179-190.
6. Budhu A., Jia H.L., Forgues M., Liu C.G., Goldstein D., Lam A., Zanetti K.A., Ye Q.H., Qin L.X., Croce C.M., et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008, 47:897-907.
7. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2:563-572.
8. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., Huang G.T., Iloeje U.H. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73. REVEAL-HBV Study Group.
9. Chen C.J., Yang H.I., Iloeje U.H. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009, 49(5, Suppl):S72-S84. REVEAL-HBV Study Group.
10. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., McGrady G., Wahl S.M. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 2003, 198:1875-1886.
11. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
12. Delaney W.E., Isom H.C. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology 1998, 28:1134-1146.
13. Ding J., Huang S., Wu S., Zhao Y., Liang L., Yan M., Ge C., Yao J., Chen T., Wan D., et al. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat. Cell Biol. 2010, 12:390-399.
14. Ding Q., Xia W., Liu J.C., Yang J.Y., Lee D.F., Xia J., Bartholomeusz G., Li Y., Pan Y., Li Z., et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol. Cell 2005, 19:159-170.
15. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6:259-269.
16. Feitelson M.A., Duan L.X. Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am. J. Pathol. 1997, 150:1141-1157.
17. Feng Y.X., Wang T., Deng Y.Z., Yang P., Li J.J., Guan D.X., Yao F., Zhu Y.Q., Qin Y., Wang H., et al. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 2011, 53:483-492.
18. Han Z. Recent progress in genomic [corrected] research of liver cancer. Sci. China C. Life Sci. 2009, 52:24-30.
19. He L., He X., Lim L.P., de Stanchina E., Xuan Z., Liang Y., Xue W., Zender L., Magnus J., Ridzon D., et al. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134.
20. Herceg Z., Paliwal A. Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome. Mutat. Res. 2011, 727:55-61.
21. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
22. Kew M.C. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2011, 26(Suppl 1):144-152.
23. Lin D.X., Zhang Q.Y., Li X., Ye Q.W., Lin F., Li L.L. An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus. J. Cancer Res. Clin. Oncol. 2011, 137:139-149.
24. Liu Y., Zhang P., Li J., Kulkarni A.B., Perruche S., Chen W. A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat. Immunol. 2008, 9:632-640.
25. Lujambio A., Lowe S.W. The microcosmos of cancer. Nature 2012, 482:347-355.
26. Lupberger J., Hildt E. Hepatitis B virus-induced oncogenesis. World J. Gastroenterol. 2007, 13:74-81.
27. Mailloux A.W., Young M.R. Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression. Crit. Rev. Immunol. 2010, 30:435-447.
28. Marotta F., Vangieri B., Cecere A., Gattoni A. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. Clin. Ter. 2004, 155:187-199.
29. Massagué J. TGFbeta in Cancer. Cell 2008, 134:215-230.
30. Matsuzaki K. Modulation of TGF-beta signaling during progression of chronic liver diseases. Front. Biosci. 2009, 14:2923-2934.
31. Morecki S., Yacovlev L., Slavin S. Effect of indomethacin on tumorigenicity and immunity induction in a murine model of mammary carcinoma. Int. J. Cancer 1998, 75:894-899.
32. Nicoloso M.S., Spizzo R., Shimizu M., Rossi S., Calin G.A. MicroRNAs-the micro steering wheel of tumour metastases. Nat. Rev. Cancer 2009, 9:293-302.
33. Ouyang W., Beckett O., Ma Q., Li M.O. Transforming growth factor-beta signaling curbs thymic negative selection promoting regulatory T cell development. Immunity 2010, 32:642-653.
34. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
35. Portolani N., Coniglio A., Ghidoni S., Giovanelli M., Benetti A., Tiberio G.A., Giulini S.M. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann. Surg. 2006, 243:229-235.
36. Quezada S.A., Peggs K.S., Curran M.A., Allison J.P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 2006, 116:1935-1945.
37. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004, 22:531-562.
38. Schmierer B., Hill C.S. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat. Rev. Mol. Cell Biol. 2007, 8:970-982.
39. Shevach E.M. CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2002, 2:389-400.
40. Shi J., Lai E.C., Li N., Guo W.X., Xue J., Lau W.Y., Wu M.C., Cheng S.Q. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann. Surg. Oncol. 2010, 17:2073-2080.
41. Siemens H., Jackstadt R., Hünten S., Kaller M., Menssen A., Götz U., Hermeking H. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011, 10:4256-4271.
42. Takizawa D., Kakizaki S., Sohara N., Sato K., Takagi H., Arai H., Katakai K., Kojima A., Matsuzaki Y., Mori M. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig. Dis. Sci. 2007, 52:3290-3295.
43. Tian J., Tang Z.Y., Ye S.L., Liu Y.K., Lin Z.Y., Chen J., Xue Q. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br. J. Cancer 1999, 81:814-821.
44. Wang T., Hu H.S., Feng Y.X., Shi J., Li N., Guo W.X., Xue J., Xie D., Liu S.R., Wu M.C., Cheng S.Q. Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma. Br. J. Cancer 2010, 102:1618-1626.
45. Xiong Y., Fang J.H., Yun J.P., Yang J., Zhang Y., Jia W.H., Zhuang S.M. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010, 51:836-845.